A recent study by Avalere found that an oncology practice’s ability to survive in the Oncology Care Model (OCM) can be dependent upon the types of cancers being treated by the practice.
According to a Managed Healthcare Executive (MHE) report, the research analyzed care costs and OCM performance-based payments for each of the 21 types of cancer in the Center for Medicare and Medicaid Innovation program aimed at delivering high-quality cancer care to Medicare patients.
“For some types of cancers, such as lung and liver cancers, it will be more difficult for clinicians to keep treatments costs below OCM target prices or to achieve high-quality scores, thus making it difficult for them to earn performance-based payments,” Avalere’s Richard Kane, senior director of policy practice, told MHE.
Avalere’s research, per the report, comes amid growing interest in understanding the OCM’s incentives due to it being an alternative payment model which affects one in five cancer patients covered by Medicare.
“Healthcare executives want to understand how the OCM payment model works, including how it may measure performance when treating certain populations or when using specific treatments,” Kane said.